Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
25 results
  • Head and Neck Cancer, Cervical Cancer, Breast Cancer, Ovarian Cancer

21-689          Phase I

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

  • Sarcoma, Thyroid Cancer, Ovarian Cancer, Lung Cancer, Pancreatic Cancer, Kidney Cancer, Head and Neck Cancer, Breast Cancer, Liver Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Sarcoma, Ovarian Cancer, Gastric (Stomach) Cancer

24-169          Phase I

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774

  • Esophageal Cancer, Cervical Cancer, Head and Neck Cancer, Ovarian Cancer, Lung Cancer, Breast Cancer

22-281          Phase I

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors

  • Esophageal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Head and Neck Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Breast Cancer, Ovarian Cancer, Melanoma, Bladder Cancer, Uterine Cancer, Endometrial Cancer, Lung Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Breast Cancer, Gastric (Stomach) Cancer, Lung Cancer, Ovarian Cancer, Esophageal Cancer, Bladder Cancer

23-679          Phase II

A Phase 1/2 Study of PRO1107 in Patients with Advanced Solid Tumors

  • Ovarian Cancer

18-227          Phase II

A Phase 1/2 Study of REGN4018 Administered Alone or in Combination with Cemiplimab in Patients with Platinum-Resistant Ovarian Cancer

  • Endometrial Cancer, Gastric (Stomach) Cancer, Ovarian Cancer, Breast Cancer

22-142          Phase II

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors

  • Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Prostate Cancer, Breast Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

Showing 1 - 10 of 25 results